Stay updated on Pembrolizumab in EOC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in EOC Clinical Trial page.

Latest updates to the Pembrolizumab in EOC Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedAdded a new page revision label 'Revision: v3.5.4' and removed the previous 'Revision: v3.5.3', indicating an update to the page metadata. The update appears to reflect record maintenance rather than changes to the study details.SummaryDifference0.1%

- Check25 days agoNo Change Detected
- Check39 days agoChange DetectedThe page’s software/version label was updated from Revision v3.5.2 to v3.5.3, indicating a minor site release without altering the clinical trial study details.SummaryDifference0.1%

- Check46 days agoChange DetectedAdded Revision: v3.5.2 and removed Revision: v3.5.0 from the page.SummaryDifference0.1%

- Check75 days agoChange DetectedPage revision updated to v3.5.0, replacing the previous v3.4.3.SummaryDifference0.1%

- Check82 days agoChange DetectedRevision label updated to v3.4.3 (previously v3.4.2). This appears to be a minor site version change and does not modify study data or content.SummaryDifference0.1%

- Check111 days agoChange DetectedFallopian tube cancer added as a condition and the page updated to version 3.4.2; the government funding status notice has been removed.SummaryDifference0.5%

Stay in the know with updates to Pembrolizumab in EOC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in EOC Clinical Trial page.